Abraham Scaria

Company: Beacon Therapeutics

Job title: Chief Scientific Officer

Seminars:

WORKSHOP A 9:30 am - 12:30 pm

Effectively reducing the doses of AAV vectors required to successfully treat patients could be the key to improving the overall safety of AAV gene therapies. However, this is easier said than done and there are several obstacles to overcome for this to become a reality for gene therapies. Join this deep dive session to learn…Read more

day: Pre-Conference Workshop Day